Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Germline BRCA Mutations in TNBC

February 15th 2018

Histologic Subtyping in TNBC

February 15th 2018

Classification of Triple Negative Breast Cancer

February 15th 2018

Blackwell Sheds Light on Recent Advances in HER2+ Breast Cancer

February 14th 2018

Kimberly L. Blackwell, MD, discusses novel agents and other recent advancements in the treatment paradigm of HER2-positive breast cancer.

Dr. King Discusses Axillary Node Dissection in Breast Cancer

February 14th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses axillary node dissection in patients with breast cancer.

Alpelisib Active in PIK3CA-Altered Solid Tumors

February 8th 2018

Alpelisib (BYL719) induced a disease control rate of 58.2% and stable disease rate of 52.2% in patients with advanced solid tumors.

Dr. Carey Discusses Findings From the CALGB40502 Trial in TNBC

February 7th 2018

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses findings from the CALGB 40502/NCCTG N063H trial in triple-negative breast cancer.

Dr. Rugo on Ongoing Trials in HER2+ Breast Cancer

February 7th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses ongoing trials for patients with HER2-positive breast cancer.

Dr. Isaacs Discusses Sacituzumab Govitecan in TNBC

February 5th 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses sacituzumab govitecan (IMMU-132) for the treatment of patients with triple-negative breast cancer.

Dr. Blackwell Discusses Tucatinib in HER2+ Breast Cancer

February 3rd 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the role of tucatinib (ONT-380) for patients with HER2-positive breast cancer.

New Model May Improve Patient Selection in Breast Cancer Trials

February 2nd 2018

A statistical model that combines multiple variables such as tumor size and lymph-node status into a single score can improve patient selection for breast cancer clinical trials and produce stronger results.

Neoadjuvant Palbociclib/Pertuzumab Regimen Active in ER/HER2-Positive Breast Cancer

February 2nd 2018

The neoadjuvant combination of palbociclib (Ibrance), pertuzumab (Perjeta), fulvestrant (Faslodex), and trastuzumab (Herceptin), cut expression of Ki67 and induced an overall clinical response of 29% in women with ER-positive/HER2-positive breast cancer.

Priority Reviews in Ovarian Cancer, Prostate Cancer, NSCLC, and More

February 2nd 2018

Treatment Landscape for HER2-Positive Breast Cancer

February 2nd 2018

Breast Cancer: Extended Adjuvant Therapy and Cost Factors

February 2nd 2018

Use of Neratinib in HER2-Positive Breast Cancer

February 2nd 2018

Chemotherapy With Adjuvant Therapy in Breast Cancer

February 2nd 2018

Adjuvant Therapy Data for HER2-Positive Breast Cancer

February 2nd 2018

Breast Cancer: Factors to Consider for Adjuvant Therapy

February 2nd 2018

Treating Patients with HER2+ Breast Cancer: Impact of Cost

February 2nd 2018